In a pioneering move, Inscripta, Inc. has unveiled its next-generation biomanufacturing capabilities to bring sustainable, high-quality anti-aging skincare ingredients to market. Leveraging its revolutionary whole-genome engineering platform, GenoScaler™, Inscripta aims to set a new standard in ingredient development with faster production timelines and more excellent supply chain stability.

The use of commercial biomanufacturing to replace traditional, plant-based ingredient sourcing addresses multiple industry challenges head-on. Extracting plant-based components has a hefty environmental toll and can suffer from limited and often inconsistent supply chains. Moreover, biomanufacturing processes can eliminate impurities that commonly trigger sensitivities in natural extracts, offering a cleaner, more reliable option for cosmetic brands and consumers alike. Inscripta has collaborated with commercial partners to bring an ingredient that promises both efficacy and consistent quality, catering to the growing demand from leading skincare brands.

The Bioeconomy’s Role in a Sustainable Future

Sri Kosaraju, President and CEO of Inscripta, sees this as just the beginning of the bioeconomy’s potential to influence global markets. “There is an incredible opportunity for the bioeconomy to meet global consumer demands, not just in personal care, but well beyond by improving sustainability, stabilizing supply chains, and reducing time to market,” Kosaraju noted. “We don’t just build productive strains; we engineer scalable manufacturing supply chains capable of delivering high-demand materials at a fraction of the traditional time and cost.”

This groundbreaking work builds upon Inscripta’s GenoScaler™ technology—a cutting-edge, CRISPR-enabled ultra-high-throughput platform that optimizes microbial strains for biomanufacturing. The company’s two-year research initiative yielded microbial strains with commercial-level productivity, performing reliably across bioreactor scales. This achievement not only validates GenoScaler’s role in streamlining development but also signifies a leap forward in producing high-performing, scalable strains ready for commercial application.

Inscripta’s Vision for Transforming Ingredient Supply Chains

Inscripta’s GenoScaler™ is more than just a technological innovation. With over 200 patents underpinning its microbial strain engineering, the platform harnesses the combined power of CRISPR, artificial intelligence, and machine learning to create biomanufacturing solutions that serve diverse industries, from agriculture to pharmaceuticals. By enabling sustainable, scalable production, Inscripta is laying the groundwork for more resilient supply chains and faster time-to-market for critical materials, driving the future of ingredient manufacturing.

For those in personal care and beyond, Inscripta’s advancements present an appealing alternative to conventional sourcing, with the promise of improved supply chain consistency, quality, and environmental impact.